Results 91 to 97 of about 562 (97)

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2016
Dave Singh, Alberto A Papi, Massimo Corradi   +2 more
exaly  

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

Lancet, The, 2017
Jørgen Vestbo, Alberto A Papi, Massimo Corradi   +2 more
exaly  

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Nature Medicine, 2018
Andrew N J Tutt, Holly Tovey, Maggie Chon U Cheang   +2 more
exaly  

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials

Lancet, The, 2019
Piotr Kuna, Pierluigi Paggiaro, Alberto A Papi   +2 more
exaly  

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

Lancet, The, 2013
Jyh-Ming Liou, Chieh-Chang Chen, Mei-Jyh Chen   +2 more
exaly  

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

Lancet, The, 2016
Jyh-Ming Liou, Chieh-Chang Chen, Ming-Jong Bair   +2 more
exaly  

Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple‐negative breast cancer

Ca-A Cancer Journal for Clinicians, 2014
exaly